Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 129-06-6 | Product Number: W0005
Warfarin Sodium (contains Isopropyl Alcohol)
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol)
Product Documents:
| Size | Unit Price | Belgium | Japan* |
|---|---|---|---|
| 5G |
€36.00
|
2 | ≥40 |
| 25G |
€135.00
|
6 | 2 |
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | W0005 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__9H__1__5NaO__4 = 330.31 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive |
| CAS RN | 129-06-6 |
| Related CAS RN | 81-81-2 |
| Reaxys Registry Number | 5469050 |
| PubChem Substance ID | 87560363 |
| Merck Index (14) | 10038 |
| MDL Number | MFCD00083223 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 91.0 % |
| 2-Propanol | 7.0 to 9.0 % |
Properties (reference)
| Solubility (slightly sol. in) | Ether, Chloroform |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H300 : Fatal if swallowed. H360 : May damage fertility or the unborn child. H370 : Causes damage to organs. H372 : Causes damage to organs through prolonged or repeated exposure. H373 : May cause damage to organs through prolonged or repeated exposure. H412 : Harmful to aquatic life with long lasting effects. |
| Precautionary Statements | P260 : Do not breathe dust. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. |
Related Laws:
| EC Number | 204-929-4 |
| RTECS# | GN4725000 |
Transport Information:
| UN Number | UN1544 |
| Class | 6.1 |
| Packing Group | II |
| HS Number | 2932209090 |
Application
Warfarin Sodium (contains Isopropyl Alcohol) Binding of Warfarin to Human Serum Albumin
Warfarin is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site I on HSA. Those were confirmed using our warfarin sodium with Surface Plasmon Resonance (SPR) and a method using fluorescent probes.
【SPR】
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
＜Assay condition＞
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.
＜Result＞
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.
＜Result＞
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
【Method using fluorescent probes】
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
＜Assay condition＞
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).
＜Result＞
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).
＜Result＞
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
In these ways, our warfarin can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.
References
- Fluorescent Dye Cocktail for Multiplex Drug￢Site Mapping on Human Serum Albumin
- High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE
- Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels
- Characterizing a drug's primary binding site on albumin
- Structural basis of the drug-binding specificity of human serum albumin
Application
Reviews of Pharmacology of Warfarin
References
- Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol
- Systematic overview of warfarin and its drug and food interactions
- Pharmacogenetics of warfarin elimination and its clinical implications
- Pharmacogenetics of warfarin: current status and future challenges
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
PubMed Literature
Articles/Brochures
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.